{"id":985896,"date":"2026-07-28T16:13:01","date_gmt":"2026-07-28T20:13:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tilray-brands-delivers-record-fiscal-2026-revenue-and-adjusted-ebitda-demonstrating-the-strength-of-its-diversified-global-platform-across-cannabis-beverage-hospitality-and-wellness\/"},"modified":"2026-07-28T16:13:01","modified_gmt":"2026-07-28T20:13:01","slug":"tilray-brands-delivers-record-fiscal-2026-revenue-and-adjusted-ebitda-demonstrating-the-strength-of-its-diversified-global-platform-across-cannabis-beverage-hospitality-and-wellness","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tilray-brands-delivers-record-fiscal-2026-revenue-and-adjusted-ebitda-demonstrating-the-strength-of-its-diversified-global-platform-across-cannabis-beverage-hospitality-and-wellness\/","title":{"rendered":"Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness"},"content":{"rendered":"
\n

\n
\n Record Fiscal Year Net Revenue of $<\/em>
\n <\/strong>
\n
\n 915<\/em>
\n <\/strong>
\n
\n Million, Record Gross Profit, Consistent Adjusted Gross Margin3<\/sup>\u00a0and Record Adjusted EBITDA5<\/sup> Highlights the Strength of Tilray\u2019s Scaled Businesses and Profitable Growth Strategy<\/em>
\n <\/strong>\n <\/p>\n

\n
\n International Medical Cannabis Revenue Increased <\/em>
\n <\/strong>
\n
\n 34%<\/em>
\n <\/strong>
\n
\n for the Fiscal Year, Reinforcing Tilray’s Leadership Across Europe and Expanding Patient Access at Scale<\/em>
\n <\/strong>\n <\/p>\n

\n
\n BrewDog Acquisition Ignited the Global Expansion of Tilray\u2019s Beverage Platform, Unlocking New Growth Through the Power of Brands, Hospitality and Consumer Experiences<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Disciplined Capital Allocation Strengthens Balance Sheet with Approximately\u00a0<\/em>
\n <\/strong>
\n
\n $235<\/em>
\n <\/strong>
\n
\n Million in Cash, Restricted Cash and Marketable Securities1<\/sup>; Net Debt2<\/sup> Reduced to $0.7<\/em>
\n <\/strong>
\n
\n Million<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Fiscal Year 2027 Guidance of Adjusted EBITDA5<\/sup> of <\/em>
\n <\/strong>
\n
\n $68<\/em>
\n <\/strong>
\n
\n Million to <\/em>
\n <\/strong>
\n
\n $75<\/em>
\n <\/strong>
\n
\n Million, Reflecting Double-Digit Growth Driven by Continued Momentum<\/em>
\n <\/strong>\n <\/p>\n

NEW YORK and LONDON and LEAMINGTON, Ontario, July 28, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (\u201cTilray\u201d, \u201cour\u201d, \u201cwe\u201d or the \u201cCompany\u201d) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, hospitality and wellness industries, today reported financial results for its fourth quarter and fiscal year ended May 31, 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.<\/p>\n

\n Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated:<\/strong> \u201cFiscal 2026 marks an important milestone in Tilray\u2019s evolution. We didn\u2019t just deliver record revenue, record gross profit and record adjusted EBITDA5<\/sup>, we demonstrated the strength of the diversified global platform we\u2019ve been building for the last five years. Today, Tilray Brands is a fundamentally different company: a global business with leadership positions across medical and adult-use cannabis, beverage, hospitality and wellness. We have built multiple growth engines, strengthened our balance sheet, expanded our global reach and created the financial flexibility to invest where we see the greatest opportunities. That combination gives us the ability to create value regardless of market conditions or regulatory timelines.\u201d<\/p>\n

Mr. Simon continued, \u201cAs we enter Fiscal 2027, we expect over $1 billion in annual revenue, with a stronger company than ever before. Across Europe, we have built one of the industry\u2019s most comprehensive medical cannabis and pharmaceutical distribution platforms. In beverages, BrewDog, our American craft beer portfolio and our Carlsberg partnership create a global platform with significant opportunities for growth. Across every part of Tilray Brands, we remain focused on disciplined execution, stronger profitability, cash flow generation and creating long-term shareholder value. The next chapter for Tilray will not be defined by one product, one market or one regulatory event. It will be defined by disciplined execution across a diversified global platform built to create enduring shareholder value. We believe the opportunity ahead for Tilray Brands is greater than ever before.\u201d<\/p>\n

\n Strategic Business Highlights<\/strong>\n <\/p>\n